HSP90B1 and bladder transitional cell carcinoma: Figure 3d shows that HSP90B1-altered patients with BLCA had an improved prognosis in progression-free survival (p = 0.0283) but not in overall survival (p = 0.216) and disease-free survival (p = 0.16) compared with HSP90B1-unaltered cases. In breast cancer, HSP90B1-altered patients showed a significantly worse prognosis in overall survival (p = 0.0166) and relapse-free survival (p = 0.0435). These findings indicate that mutations in the HSP90B1 gene could affect the prognosis of individuals with varying malignancies.